Ebola virus pathogenesis: implications for vaccines and therapies.
about
The Tyro3 receptor kinase Axl enhances macropinocytosis of Zaire ebolavirusCNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV)Clinical development of Ebola vaccinesPrevalence and Current Approaches of Ebola Virus Disease in ASEAN CountriesEbola Virus Disease (The Killer Virus): Another Threat to Humans and Bioterrorism: Brief Review and Recent UpdatesProgress of vaccine and drug development for Ebola preparednessEbola hemorrhagic Fever and the current state of vaccine developmentEbola virus: A gap in drug design and discovery - experimental and computational perspective.Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels.How Ebola impacts genetics of Western lowland gorilla populations.Glc1.8 from Microplitis demolitor bracovirus induces a loss of adhesion and phagocytosis in insect high five and S2 cells.Rapid deployment of a mobile biosafety level-3 laboratory in Sierra Leone during the 2014 Ebola virus epidemic.Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteinsHuman Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.Ebola hemorrhagic fever: current outbreak and progress in finding a cure.A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trialSuccessful delivery of RRT in Ebola virus diseaseFilovirus emergence and vaccine development: a perspective for health care practitioners in travel medicineIn silico analysis suggests interaction between Ebola virus and the extracellular matrixThe deadly ebola threat in the midst of an overwhelming dengue epidemic.Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.Towards detection and diagnosis of Ebola virus disease at point-of-care.Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus.Development of vaccines for Marburg hemorrhagic fever.Two synthetic antibodies that recognize and neutralize distinct proteolytic forms of the ebola virus envelope glycoprotein.Stimulation of Ebola virus production from persistent infection through activation of the Ras/MAPK pathway.Disease modeling for Ebola and Marburg viruses.Conformational properties of peptides corresponding to the ebolavirus GP2 membrane-proximal external region in the presence of micelle-forming surfactants and lipids.Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors.Viral glycoproteins: biological role and application in diagnosis.Adenovirus-vectored Ebola vaccines.Windows of opportunity for Ebola virus infection treatment and vaccination.Retracted: Ebola virus: an introduction and its pathology.Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes.Non-active site mutations disturb the loop dynamics, dimerization, viral budding and egress of VP40 of the Ebola virus.Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro.Analysis of Ebola virus polymerase domains to find strain-specific differences and to gain insight on their pathogenicity.Genetic Changes at the Glycoprotein Editing Site Associated With Serial Passage of Sudan Virus.Point/counterpoint. Radiotherapy is an appropriate treatment to consider for patients infected with the Ebola virus.Against Ebola: type I interferon guard risk and mesenchymal stromal cell combat sepsis.
P2860
Q24305409-EF96B9FC-6F24-46F1-A4A1-35059EC64329Q24800765-74E52E4E-3F40-4EBB-B193-20022C6D6808Q26775792-08B55D4D-6384-40F6-B8A0-F783331C28B3Q26779109-E9B09905-3AA7-4E73-8A71-06E1239621C7Q26798860-F57AEAFD-0D38-4050-9421-CDCEEA4E62D4Q30204870-DFA0A17A-B7E0-44AB-A963-72BB6B57F818Q30205198-D81ED391-7DAF-4234-9343-5D6DE8C5A039Q30243938-EE7BD5CD-EC37-4E23-BB5D-FD5487DF68EFQ33362611-0D7336B6-07C1-4A10-84A1-09CD41C2C876Q33519551-25E01490-2372-4DAE-85F9-ACF5DF902873Q33718649-E570B9BF-745E-4F00-8D16-8A346ECFE7CFQ33728729-5E3C8BE8-7333-477D-B757-E02978DAC653Q34123838-73C4BE13-5938-4354-9F51-C7C19413CFF1Q34463780-43112614-F87F-48A8-BE8A-3ECE1B52EB8EQ34491250-1DFFAECB-E73A-433D-9DA1-F1B21B024B22Q34571072-213E7BDF-23C7-4D7D-869B-93595F8D0184Q34787843-46B4DE03-6A14-4E88-95C2-DEF41F838BC4Q35048254-AD36C71C-41D1-4E07-BAE9-835D4F73CD5CQ35099536-CFA0BFD6-BF75-4C25-A06F-EFA24757AF00Q35340980-6A4862A1-B44D-41EB-A5E8-5D2B8DA9CB38Q36043296-7F72102D-633B-4904-B3A0-CB826895ABACQ36148222-F96B80C8-DF75-4BD4-877D-25B1ED8E216CQ36591830-37FC943C-CC2E-4227-87E2-0564A2AA692EQ36728793-1B1D3F3A-6659-426E-B6DB-303D853B0AB3Q36934038-922DDF14-FFB6-4D50-8C06-19A3A1BD5A7EQ36960705-58263583-787C-4469-8A47-0E4D9EDD7EB0Q37040575-68FB5439-E1B6-44F6-8827-0DCD31BB9FC0Q37170473-82C38F16-707D-4152-B97C-A80ADFA0EB77Q37355990-B86EEF8E-8700-40A7-9991-EAA8DE98DF99Q38543883-E5A7897C-88A7-45DE-B133-6542C1A32401Q38569831-472A823C-11B6-4B70-9A8F-2BF1875BD0DAQ38615306-AB293910-F0BE-4336-806C-7D64EE6DD90DQ38630575-742CF29D-873B-4BA6-8992-D8F44145BDDEQ38877091-9DC1511B-3B61-44C1-8E05-1760D8C05CCAQ38974306-13ACD860-27B4-41AC-B72D-F8545CF32763Q39129671-3171EE18-D1F4-4D44-A308-27A301132E00Q40058733-8F7FA56F-5A30-4D12-9713-F93637FBD34DQ40158371-C27EB8A4-A178-44A3-A405-D87A55E16973Q40167063-FC2E9598-58DA-4FC9-8404-02690A5E15E8Q40175069-9D78FC63-C19C-4A80-8358-F6830692A649
P2860
Ebola virus pathogenesis: implications for vaccines and therapies.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Ebola virus pathogenesis: implications for vaccines and therapies.
@ast
Ebola virus pathogenesis: implications for vaccines and therapies.
@en
type
label
Ebola virus pathogenesis: implications for vaccines and therapies.
@ast
Ebola virus pathogenesis: implications for vaccines and therapies.
@en
prefLabel
Ebola virus pathogenesis: implications for vaccines and therapies.
@ast
Ebola virus pathogenesis: implications for vaccines and therapies.
@en
P2860
P921
P1433
P1476
Ebola virus pathogenesis: implications for vaccines and therapies.
@en
P2093
Nancy Sullivan
P2860
P304
P356
10.1128/JVI.77.18.9733-9737.2003
P407
P577
2003-09-01T00:00:00Z